Ketorolac Eg (Ketorolac Trometamol)

Ketorolac works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish inflammation and pain signaling at the site of tissue injury.

The specific oral dose of ketorolac is determined by the prescribing clinician based on the patient’s condition, age, renal function, and other factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for ketorolac during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ketorolac is generally more potent as an analgesic compared with many traditional NSAIDs, making it suitable for short‑term, high‑intensity pain control. However, its risk profile for gastrointestinal and renal adverse effects is also higher, so it is reserved for brief use under medical supervision.

Ketorolac Eg should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Ketorolac Eg is administered orally, usually as a tablet or oral solution, and should be taken with a full glass of water. It may be taken with or without food, but taking it with food can reduce gastrointestinal irritation.

Serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, cardiovascular events such as myocardial infarction or stroke, and severe allergic reactions including anaphylaxis. Patients should seek immediate medical attention if they experience signs of these conditions.

Ketorolac is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, active gastrointestinal bleeding or ulcer disease, severe renal impairment, advanced heart failure, and in the peri‑operative setting for coronary artery bypass graft surgery. It should also be avoided in patients receiving certain anticoagulants without careful risk assessment.